Breast implants are inadequate and outdated. There are 300,000 cosmetic breast and 160,000 breast reconstruction procedures per year in the US. 33% of reconstructions develop complications and 66,000 implants are removed yearly and increasing. Silicone implants have a limited lifespan and a ‘black box’ FDA warning due to complications from capsular contracture, migration, infection, and rupture. There are 200,000 lumpectomies per year and zero lumpectomy implants, limiting reconstruction options. Additionally, +20% of lumpectomies have positive cancer margins after tumor removal requiring re-excision. 

GenesisTissue Inc. is developing the future of breast surgery. Regenerative Breast Tissue (RBT) is a 3D bioprinted implantable scaffold that is made of a degradable material that is soft, feels like breast tissue, and mechanically supports an injected fat graft harvested from the patient’s own body. RBT regenerates to become native tissue without risk of rejection, can be personalized to fit the defect, and is scalable to cosmetic breast surgery and many other soft tissues throughout the body. 

All women deserve the ability to be reconstructed after breast cancer, the RBT solution will make a life-long reconstruction accessible to all breast cancer patients. GenesisTissue turns every breast surgeon into a plastic surgeon; one who can perform, bill, and get paid for inserting an RBT implant into their patients. RBT regenerates into native tissue and will not need to be replaced, reducing cost of care by decreasing complications and repeat surgeries. RBT is a safer alternative versus traditional silicone breast implants.